Regional citrate versus heparin anticoagulation for CRRT in critically ill patients: a meta-analysis of RCTS.
Regional citrate versus heparin anticoagulation for CRRT in critically ill patients: a meta-analysis of RCTS.
Rui Li,Xiang Gao,3 作者,Pei-lei Zhang
2021 · DOI: 10.37766/inplasy2021.12.0093
Therapeutic apheresis and dialysis · 引用数 0
TLDR
Citrate anticoagulant therapy should have priority for CRRT in most critically ill patients, and there no difference existed in mortality, metabolic alkalosis, circuit loss, and the number of transfused between the two groups.
摘要
INTRODUCTION
This study aimed to compare the efficacy and safety of citrate and heparin in continuous renal replacement therapy (CRRT) for critically ill patients.METHODS
Searched in PubMed, Embase, and Cochrane Library databases.RESULTS
Analyses showed that there no difference existed in mortality, metabolic alkalosis, circuit loss, and the number of transfused between the two group(RR=0.95, P=0.40; RR=1.73, P=0.40; RR=0.64, P=0.09; RR=1.05, P=0.70). The filter life of the citrate group was longer than heparin group(MD=16.98, P<0.0001). The risk of bleeding and HIT was significantly lower in the citrate(RR=0.32, P<0.00001; RR=0.55, P=0.04). The citrate group was more susceptible to hypocalcemia(RR=4.85, P=0.0004).CONCLUSION
Citrate anticoagulant therapy should have priority for CRRT in most critically ill patients. This article is protected by copyright. All rights reserved.